MCM
RNAC icon

MAI Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

MAI Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24
Closed -$148 – 4162
2026
Q1 		$148 Buy
+24
New +$171 ﹤0.01% 4686

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MAI Capital Management's RNAC Position: Q2 2026 in Review

MAI Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2026, closing a stake of 24 shares — an estimated $148 sold.

MAI Capital Management first reported a position in RNAC in Q1 2026 and held it in 1 quarter. The position peaked at $148 in Q1 2026. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • MAI Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 24 Cartesian Therapeutics shares in Q2 2026, an estimated $148.
  • MAI Capital Management first reported a position in Cartesian Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Cartesian Therapeutics position peaked at $148 in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.